FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition having pyruvate kinase (PKR) activator activity containing an effective amount of a compound of formula I, where values of R1-R11, R1'-R11', Y are specified in the claim.
EFFECT: pharmaceutical composition is intended for treating diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase (PKD) insufficiency, sickle cell disease (SCD) and thalassemia.
24 cl, 1 dwg, 7 tbl, 46 ex
Title | Year | Author | Number |
---|---|---|---|
8-CARBAMOYL-2-(2,3-DI-SUBSTITUTED PYRID-6-YL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS-INDUCING AGENTS FOR CANCER TREATMENT | 2012 |
|
RU2625315C2 |
BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | 2018 |
|
RU2776846C2 |
APOPTOSIS-INDUCING AGENTS | 2018 |
|
RU2782469C2 |
METHOD FOR INHIBITION OF RAF KINASE-MEDIATED GROWTH OF TUMOR CELLS, HETEROCYCLIC UREA DERIVATIVES (VARIANTS), PHARMACEUTICAL COMPOSITION (VARIANTS) | 1998 |
|
RU2232015C2 |
MEK INHIBITORS AND THEIR THERAPEUTIC USE | 2021 |
|
RU2812929C1 |
COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
AGENTS CAUSING APOPTOSIS AND INTENDED FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2012 |
|
RU2594282C2 |
NEW BICYCLIC COMPOUNDS AS DUAL INHIBITORS OF ATX/CA | 2016 |
|
RU2724899C2 |
SPIROHETEROCYCLIC COMPOUNDS AND USE THEREOF AS THERAPEUTIC AGENTS | 2006 |
|
RU2428424C2 |
METHOD OF PRODUCING ISOTHIAZOLE DERIVATIVES | 2005 |
|
RU2349588C2 |
Authors
Dates
2020-11-12—Published
2018-03-20—Filed